Recent

% | $
Quotes you view appear here for quick access.

Synergy Pharmaceuticals, Inc. Message Board

  • cabogordon cabogordon Feb 27, 2013 12:44 PM Flag

    clairty: IBD versus IBS

    plecanatide was designed to treat IBD. All the trials have been extremely positive. This drug is SGYP lead drug and why most are investors are here. SGYP is also developing second drug a syntheitc form of plecanatide called SP-333 for IBD. This is in phase one trial and a added value of it works. Magnum posts is challenging SP-333 not plecanatide for the treatment IBS... Does that make sense to everyone ?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Magnum_pi is another self-proclaimed "specialist" just good to mix apples and oranges because he likes to foul everyone with a false expertise of either "how to get a patent" or if the release of SP-333 is into the large intestine or in the small intestine or in the duodenum or where the disulfide has a better activity...etc ! What a false debate and wrong arguments to judge SGYP. Many times we find "Gurus" like him saying nonsense and we have to answer to these guys with no scientific background especially in biology or in fondamental research. What a shame !

      Sentiment: Strong Buy

    • Correction. Placantide was designed for IBS ......

 
SGYP
4.44+0.09(+2.07%)May 26 4:00 PMEDT